Context Therapeutics Inc (CNTX) 13F Investor Activity Report (Q2 2026)

CNTX ranks #5071 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

81 institutions disclose a position in CNTX, but none treat it as a major bet — even Avidity Partners Management LP, its most concentrated holder, allocates just 0.4% of its own portfolio to it.

FNY Investment Advisers, LLC has trimmed its CNTX position for two straight quarters, cutting it by $14.0K while still holding $1.0K.

CNTX is up 1.2% today, but institutions show net selling of $2.5M this quarter — a divergence between today's price move and the underlying institutional flow.

CNTX reported a net loss of $36.1M in its latest fiscal year.

• Not yet profitable — net loss of $36.1M in the latest fiscal year
• Net income declined year over year, from -$26.7M to -$36.1M
• Operating cash flow was negative, using $26.4M in cash
• Current ratio of 8.52x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.13x equity — within a conventional range